10:04 AM EST - Cardiol Therapeutics Inc. : Has received approval from Health Canada to proceed with the Company's Phase II, multi-center, double-blind, randomized, placebo-controlled trial designed to study the safety and tolerability of CardiolRx™ as well as its impact on myocardial recovery in patients presenting with acute myocarditis. Cardiol Therapeutics Inc.
shares T.CRDL are trading down $0.15 at $5.30.
